Kolltan signs research agreement with CHOP for novel therapeutic approaches for neuroblastoma

Kolltan Pharmaceuticals, Inc., a privately held biopharmaceutical company, today announced a license and research agreement with The Children's Hospital of Philadelphia (CHOP) to commence a collaboration with Yaël Mossé, M.D, an internationally recognized clinician and scientist for her work studying the causes and novel therapeutic approaches for the treatment of children diagnosed with neuroblastoma.

“We are excited to begin our scientific effort with CHOP and look forward to our collaboration focused on this novel receptor tyrosine kinase target for the treatment of cancers that affect many children”

"We are excited to begin our scientific effort with CHOP and look forward to our collaboration focused on this novel receptor tyrosine kinase target for the treatment of cancers that affect many children", commented Jerry McMahon, Ph.D., Kolltan's President and Chief Executive Officer. "This collaboration is representative of Kolltan's work with leading academic researchers and clinicians and exemplifies our commitment to creating novel biologic products for cancers in select cancer types where receptor tyrosine kinases play a key role."

Dr. Mossé stated, "While small molecule inhibition of ALK remains a promising strategy for the subset of patients with an ALK mutation or amplification, development of ALK-targeted immunotherapy or antibody-drug conjugates also may enhance the response in those cells. We believe immunotherapy and ADCs may provide a therapeutic option for the majority of patients with high-risk disease given the widespread expression of ALK on the cell surface of most neuroblastoma tumors."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Leveraging the power of automation to boost research